These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 30306859)

  • 81. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
    Reiner Ž
    Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
    [TBL] [Abstract][Full Text] [Related]  

  • 83. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
    Sible AM; Nawarskas JJ; Anderson JR
    Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
    Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
    Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
    [TBL] [Abstract][Full Text] [Related]  

  • 85. New Trends in Dyslipidemia Treatment.
    Jang AY; Lim S; Jo SH; Han SH; Koh KK
    Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy].
    Wallemacq C
    Rev Med Liege; 2017 Nov; 72(11):505-512. PubMed ID: 29171950
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
    Turgeon RD; Pearson GJ
    Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Umbrella Review on Non-Statin Lipid-Lowering Therapy.
    Beshir SA; Hussain N; Elnor AA; Said ASA
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):437-452. PubMed ID: 33836639
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Small molecules as inhibitors of PCSK9: Current status and future challenges.
    Xu S; Luo S; Zhu Z; Xu J
    Eur J Med Chem; 2019 Jan; 162():212-233. PubMed ID: 30448414
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
    Galema-Boers AMH; Lenzen MJ; Sijbrands EJ; Roeters van Lennep JE
    J Clin Lipidol; 2017; 11(3):674-681. PubMed ID: 28506389
    [TBL] [Abstract][Full Text] [Related]  

  • 91. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
    Stein EA
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.
    Surma S; Romańczyk M; Filipiak KJ
    Cardiol J; 2023; 30(1):131-142. PubMed ID: 33470417
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Current and future trends in the treatment of dyslipidemias.
    Vrablík M
    Vnitr Lek; 2019; 65(10):643-650. PubMed ID: 31906686
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Alirocumab for the treatment of hypercholesterolemia.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Biol Ther; 2017 May; 17(5):633-643. PubMed ID: 28277798
    [TBL] [Abstract][Full Text] [Related]  

  • 96. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis.
    Squizzato A; Suter MB; Nerone M; Giugliano RP; Dentali F; Maresca AM; Campiotti L; Grandi AM; Guasti L
    Intern Emerg Med; 2017 Oct; 12(7):1043-1053. PubMed ID: 28695455
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
    Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
    N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 100. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes.
    Hess CN; Low Wang CC; Hiatt WR
    Annu Rev Med; 2018 Jan; 69():133-145. PubMed ID: 29095667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.